NBIX snapped up after hitting a new yearly low and falling below the bands set on an 80 SMA. Price returns to the bands on this setting eventually. When price is over the bands on this setting, then it will usually go down to settle back inside the bands. (orange arrow at top)
Price being below the bands exhibits a lot of selling pressure, but when selling is exhausted, then there are buyers. Large volume bar earlier in the year marked with a green star. I know I did not generate that massive volume (o: so I guesstimate someone would come back in and save the investment they made that day. I could be wrong about that but just seems so. I know I would!
I do not think I would want to be in NBIX at earnings as it does not look like they meet the numbers. I am watching this one, but I bought a tiny bit yesterday. Something told me to hold my horses and be a bit more confident.
PE 31.77 EPS 2.84 and looks like revenue grows quarter to quarter. Short interest is 4.44%.
Much of the Biotech sector is at or close to it's bottom. Stocks like GH and the ETF, XBI seem to be settling down
"Ingrezza prescriptions really depend upon face-to-face visits with prescribing physicians, and COVID-19 restrictions further hamper the company's sales and physician education efforts." So news I see on this one is on the negative side, as I suppose that due to the political virus, some there will no longer be face to face doctor visits?? Is not seeing your doctor in person considered healthy? Dunno about that one but it is what it is.
No recommendation. Don't forget to take a look in the rearview mirror (o:
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson’s disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington’s disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for treating rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company’s products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for treating anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.
Price being below the bands exhibits a lot of selling pressure, but when selling is exhausted, then there are buyers. Large volume bar earlier in the year marked with a green star. I know I did not generate that massive volume (o: so I guesstimate someone would come back in and save the investment they made that day. I could be wrong about that but just seems so. I know I would!
I do not think I would want to be in NBIX at earnings as it does not look like they meet the numbers. I am watching this one, but I bought a tiny bit yesterday. Something told me to hold my horses and be a bit more confident.
PE 31.77 EPS 2.84 and looks like revenue grows quarter to quarter. Short interest is 4.44%.
Much of the Biotech sector is at or close to it's bottom. Stocks like GH and the ETF, XBI seem to be settling down
"Ingrezza prescriptions really depend upon face-to-face visits with prescribing physicians, and COVID-19 restrictions further hamper the company's sales and physician education efforts." So news I see on this one is on the negative side, as I suppose that due to the political virus, some there will no longer be face to face doctor visits?? Is not seeing your doctor in person considered healthy? Dunno about that one but it is what it is.
No recommendation. Don't forget to take a look in the rearview mirror (o:
Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological, endocrine, and psychiatric-based diseases and disorders in the United States. The company offers INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia; ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson’s disease; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for the treatment of endometriosis pain; and ORIAHNN, a GnRH antagonist for the management of heavy menstrual bleeding associated with uterine fibroids. Its product candidates in clinical development include valbenazine, which is in Phase III clinical trial for the treatment of chorea in Huntington’s disease; NBI-921352, a Nav1.6 sodium channel inhibitor for the treatment of pediatric patients, as well as other indications, such as adult focal epilepsy; NBI-827104, an orally active and brain penetrating T-type calcium channel blocker for treating rare pediatric epilepsy and other indications; and NBI-74788, which is in Phase III clinical trial for the treatment of congenital adrenal hyperplasia. The company’s products under development include NBI-1065844, a D-amino acid oxidase inhibitor for the treatment of negative symptoms of schizophrenia; NBI-1065845, an alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid potentiator for the treatment of resistant depression; and NBI-1065846, a G protein-coupled receptor 139 agonist for treating anhedonia in depression. It has collaborations and agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was founded in 1992 and is headquartered in San Diego, California.